NCT04158050View on ClinicalTrials.gov

Comparison of Biologicals in Treatment of Severe Asthma

CompletedOBSERVATIONAL
Enrollment

64

Participants

Timeline

Start Date

January 1, 2018

Primary Completion Date

October 31, 2020

Study Completion Date

October 31, 2020

Conditions
Asthma
Interventions
DRUG

IL5 Antagonist or anti-IL5R-antibody or Omalizumab

mepolizumab, reslizumab, benralizumab and omalizumab in severe asthma

Trial Locations (1)

00029

Helsinki University Central Hospital, Helsinki

All Listed Sponsors
collaborator

Ida Montini Foundation

OTHER

lead

Helsinki University Central Hospital

OTHER

NCT04158050 - Comparison of Biologicals in Treatment of Severe Asthma | Biotech Hunter | Biotech Hunter